近日，深圳市瑞图生物技术有限公司宣布成功完成超亿元B2轮融资。该公司是一家聚焦人工智能与医学诊断深度融合的AI生物医学初创公司。本轮融资由国科投资、国内知名基金领投，深投控资本参与投资，点石资本担任独家财务顾问。
据悉，瑞图生物一直致力于将人工智能技术应用于医学诊断领域，通过深度学习和大数据分析等技术手段，为医生提供更加精准、高效的诊断方案。此次融资将有助于瑞图生物进一步加大研发投入，推动其在人工智能与医学诊断领域的技术创新。
国科投资是国内领先的科技产业投资机构之一，其投资方向主要集中在高科技领域。此次领投瑞图生物的B2轮融资，表明了国科投资对于人工智能与医学诊断深度融合领域的高度认可。
此外，深投控资本也参与了本轮融资。作为深圳市政府设立的投资平台，深投控资本一直致力于支持本地科技创新企业的发展。此次参与瑞图生物的融资，无疑将为后者未来的发展提供有力支持。
英语如下：
====
“Headline: AI Biomedical Giant ‘Rittu Biotech’ Completes====
“Headline: AI Biomedical Giant ‘Rittu Biotech’ Completes Over 100 Million B2 Round of Financing
Keywords: Rittu Biotech, B2 round of financing, AI medicine
News Content: Recently, Shenzhen Rittu Biotechnology Co., Ltd announced the successful completion of its over 100 million yuan B2 round of financing. The company is an AI biomedical start-up that focuses on the deep integration of artificial intelligence and medical diagnosis. This round of financing was led by Guokai Investment and domestic well-known funds, with Shenzhen Investment Control Capital participating in the investment, and Dianshi Capital serving as the exclusive financial advisor.
It is reported that Rittu Biotech has been committed to applying artificial intelligence technology to the field of medical diagnosis, providing doctors with more accurate and efficient diagnostic solutions through technologies such as deep learning and big data analysis. This financing will help Rittu Biotech further increase its R&D investment and promote technological innovation in the field of AI and medical diagnosis.
Guokai Investment is one of the leading technology industry investment institutions in China, with its investment focus mainly in high-tech fields. The lead investment in Rittu Biotech’s B2 round of financing demonstrates Guokai Investment’s high recognition of the field of deep integration of artificial intelligence and medical diagnosis.
In addition, Shenzhen Investment Control Capital also participated in this round of financing. As an investment platform established by the Shenzhen Municipal Government, Shenzhen Investment Control Capital has been committed to supporting the development of local technology innovation enterprises. Its participation in Rittu Biotech’s financing will undoubtedly provide strong support for the latter’s future development.”
【来源】https://www.vbdata.cn/1518942969
Views: 1